These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 33048929)

  • 1. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
    Bernard CL; Rao IJ; Robison KK; Brandeau ML
    PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
    Bernard CL; Owens DK; Goldhaber-Fiebert JD; Brandeau ML
    PLoS Med; 2017 May; 14(5):e1002312. PubMed ID: 28542184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
    Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
    Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
    Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
    Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness and cost-effectiveness of diversion and aftercare programmes for offenders using class A drugs: a systematic review and economic evaluation.
    Hayhurst KP; Leitner M; Davies L; Flentje R; Millar T; Jones A; King C; Donmall M; Farrell M; Fazel S; Harris R; Hickman M; Lennox C; Mayet S; Senior J; Shaw J
    Health Technol Assess; 2015 Jan; 19(6):1-168, vii-viii. PubMed ID: 25619533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of criminal justice and substance use treatment involvement with HIV/HCV testing and the HIV treatment cascade among people who use drugs in Oakland, California.
    Lambdin BH; Kral AH; Comfort M; Lopez AM; Lorvick J
    Addict Sci Clin Pract; 2017 Jun; 12(1):13. PubMed ID: 28610602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
    Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
    Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis.
    Ward Z; Stone J; Bishop C; Ivakin V; Eritsyan K; Deryabina A; Low A; Cepeda J; Kelly SL; Heimer R; Cook R; Altice FL; Litz T; Terlikbayeva A; El-Bassel N; Havarkov D; Fisenka A; Boshnakova A; Klepikov A; Saliuk T; Deshko T; Vickerman P
    Lancet HIV; 2022 Jan; 9(1):e42-e53. PubMed ID: 34895484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation.
    Hancock E; Ward Z; Ayres R; Neale J; Hussey D; Kesten JM; Hickman M; Vickerman P
    Addiction; 2020 Apr; 115(4):702-713. PubMed ID: 31633849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the impact and cost-effectiveness of non-governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine.
    Stone J; Trickey A; Walker JG; Bivegete S; Semchuk N; Sazonova Y; Varetska O; Altice FL; Saliuk T; Vickerman P
    J Int AIDS Soc; 2023 Apr; 26(4):e26073. PubMed ID: 37012669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs.
    Sweeney S; Ward Z; Platt L; Guinness L; Hickman M; Hope V; Maher L; Iversen J; Hutchinson SJ; Smith J; Ayres R; Hainey I; Vickerman P
    Addiction; 2019 Mar; 114(3):560-570. PubMed ID: 30674091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
    Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
    Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
    Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
    J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.
    Schackman BR; Leff JA; Barter DM; DiLorenzo MA; Feaster DJ; Metsch LR; Freedberg KA; Linas BP
    Addiction; 2015 Jan; 110(1):129-43. PubMed ID: 25291977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
    Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities.
    Krebs E; Zang X; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Gebo KA; Marshall BDL; Mehta SH; Metsch LR; Pandya A; Schackman BR; Strathdee SA; Nosyk B;
    J Infect Dis; 2020 Sep; 222(Suppl 5):S301-S311. PubMed ID: 32877548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
    Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
    J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study.
    Uyei J; Fiellin DA; Buchelli M; Rodriguez-Santana R; Braithwaite RS
    Lancet Public Health; 2017 Mar; 2(3):e133-e140. PubMed ID: 29253386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.